127 related articles for article (PubMed ID: 22021170)
21. [Comparison of polyethylene glycol conjugated asparaginase and L-asparaginase for treatment of childhood acute lymphoblastic leukemia].
Cooperation Group of Phase II Clinical Trial of PEG-Asp
Zhonghua Xue Ye Xue Za Zhi; 2008 Jan; 29(1):29-33. PubMed ID: 18512312
[TBL] [Abstract][Full Text] [Related]
22. [New possibilities of treatment with PEG-L-asparaginase in patients with acute lymphoblastic leukemia sensitized to l-asparaginase E.coli and erwinase].
Sikorska-Fic B; Makowska K; Rokicka-Milewska R
Wiad Lek; 1998; 51 Suppl 4():233-6. PubMed ID: 10731974
[TBL] [Abstract][Full Text] [Related]
23. Delayed allergic reactions following intramuscular L-asparaginase.
Spiegel RJ; Echelberger CK; Poplack DG
Med Pediatr Oncol; 1980; 8(2):123-5. PubMed ID: 6932563
[TBL] [Abstract][Full Text] [Related]
24. Toxicity, pharmacology and feasibility of administration of PEG-L-asparaginase as consolidation therapy in patients undergoing bone marrow transplantation for acute lymphoblastic leukemia.
Graham ML; Asselin BL; Herndon JE; Casey JR; Chaffee S; Ciocci GH; Daeschner CW; Davis AR; Gold S; Halperin EC; Laughlin MJ; Martin PL; Olson JF; Kurtzberg J
Bone Marrow Transplant; 1998 May; 21(9):879-85. PubMed ID: 9613779
[TBL] [Abstract][Full Text] [Related]
25. Alternative algorithm for L-asparaginase allergy in children with acute lymphoblastic leukemia.
Soyer OU; Aytac S; Tuncer A; Cetin M; Yetgin S; Sekerel BE
J Allergy Clin Immunol; 2009 Apr; 123(4):895-9. PubMed ID: 19081614
[TBL] [Abstract][Full Text] [Related]
26. Asparagine concentration in plasma after 2,500 IU/m(2) PEG-asparaginase i.v. in children with acute lymphoblastic leukemia.
Wenner KA; Vieira Pinheiro JP; Escherich G; Wessalowski R; Jorch N; Wolff J; Stehn M; Kohlschütter A; Boos J; Janka-Schaub GE
Klin Padiatr; 2005; 217(6):321-6. PubMed ID: 16307417
[TBL] [Abstract][Full Text] [Related]
27. Anaphylactic reaction to polyethylene-glycol conjugated-asparaginase: premedication and desensitization may not be sufficient.
Sahiner UM; Yavuz ST; Gökce M; Buyuktiryaki B; Altan I; Aytac S; Tuncer M; Tuncer A; Sackesen C
Pediatr Int; 2013 Aug; 55(4):531-3. PubMed ID: 23910807
[TBL] [Abstract][Full Text] [Related]
28. Pegasparaginase: where do we stand?
Zeidan A; Wang ES; Wetzler M
Expert Opin Biol Ther; 2009 Jan; 9(1):111-9. PubMed ID: 19063697
[TBL] [Abstract][Full Text] [Related]
29. Retrospective cohort study monitoring PEG-asparaginase activity in acute lymphoblastic leukemia patients with and without premedication.
Losasso M; Bostrom B; Messinger Y
F1000Res; 2019; 8():1007. PubMed ID: 32089823
[No Abstract] [Full Text] [Related]
30. Antibodies Predict Pegaspargase Allergic Reactions and Failure of Rechallenge.
Liu Y; Smith CA; Panetta JC; Yang W; Thompson LE; Counts JP; Molinelli AR; Pei D; Kornegay NM; Crews KR; Swanson H; Cheng C; Karol SE; Evans WE; Inaba H; Pui CH; Jeha S; Relling MV
J Clin Oncol; 2019 Aug; 37(23):2051-2061. PubMed ID: 31188727
[TBL] [Abstract][Full Text] [Related]
31. Allergic-like reactions to asparaginase: Atypical allergies without asparaginase inactivation.
Kloos RQ; Pieters R; Escherich G; van der Sluis IM
Pediatr Blood Cancer; 2016 Nov; 63(11):1928-34. PubMed ID: 27376478
[TBL] [Abstract][Full Text] [Related]
32. Outcomes Following Discontinuation of E. coli l-Asparaginase Upon Severe Allergic Reactions in Children With Acute Lymphoblastic Leukemia.
Yen HJ; Chang WH; Liu HC; Yeh TC; Hung GY; Wu KH; Peng CT; Chang YH; Chang TK; Hsiao CC; Sheen JM; Chao YH; Chang TT; Chiou SS; Lin PC; Wang SC; Lin MT; Ho WL; Chen YC; Liang DC
Pediatr Blood Cancer; 2016 Apr; 63(4):665-70. PubMed ID: 26703788
[TBL] [Abstract][Full Text] [Related]
33. Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia.
Hak LJ; Relling MV; Cheng C; Pei D; Wang B; Sandlund JT; Rubnitz J; Pui CH
Leukemia; 2004 Jun; 18(6):1072-7. PubMed ID: 15057247
[TBL] [Abstract][Full Text] [Related]
34. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL).
Dinndorf PA; Gootenberg J; Cohen MH; Keegan P; Pazdur R
Oncologist; 2007 Aug; 12(8):991-8. PubMed ID: 17766659
[TBL] [Abstract][Full Text] [Related]
35. Adverse effects of pegaspargase in pediatric patients receiving doses greater than 3,750 IU.
Lebovic R; Pearce N; Lacey L; Xenakis J; Faircloth CB; Thompson P
Pediatr Blood Cancer; 2017 Oct; 64(10):. PubMed ID: 28436558
[TBL] [Abstract][Full Text] [Related]
36. [Long-term infusion of L-asparaginase--an alternative to intramuscular injection?].
Rodriguez T; Baumgarten E; Fengler R; Soumpasis D; Henze G
Klin Padiatr; 1995; 207(4):207-10. PubMed ID: 7564153
[TBL] [Abstract][Full Text] [Related]
37. Oncologist counseling practice and COVID-19 vaccination outcomes for patients with history of PEG-asparaginase hypersensitivity.
Zarnegar-Lumley S; Stone CA; Smith CM; Hall LL; Luck KE; Koo G; Plager JH; Phillips EJ; Friedman DL
Pediatr Blood Cancer; 2022 Jul; 69(7):e29686. PubMed ID: 35353440
[TBL] [Abstract][Full Text] [Related]
38.
Liu S; Gao C; Wu Y; Lin W; Li J; Xue T; Wang L; Zheng H; Zhang R
Pharmacogenomics; 2021 Nov; 22(17):1135-1142. PubMed ID: 34747637
[No Abstract] [Full Text] [Related]
39. Therapeutic drug monitoring of asparaginase in the ALL-BFM 2000 protocol between 2000 and 2007.
Schrey D; Borghorst S; Lanvers-Kaminsky C; Hempel G; Gerss J; Möricke A; Schrappe M; Boos J
Pediatr Blood Cancer; 2010 Jul; 54(7):952-8. PubMed ID: 20108339
[TBL] [Abstract][Full Text] [Related]
40. Antimetabolite-based therapy in childhood T-cell acute lymphoblastic leukemia: a report of POG study 9296.
Winter SS; Holdsworth MT; Devidas M; Raisch DW; Chauvenet A; Ravindranath Y; Ducore JM; Amylon MD
Pediatr Blood Cancer; 2006 Feb; 46(2):179-86. PubMed ID: 16007607
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
